InfuSystem Holdings, Inc. logo

InfuSystem Holdings, Inc.

INFU

AMEXHealthcareMedical - Devices

Previous close

$12.21

+$0.01 · +0.08%

Aug 21, 4:00 PM ET

INFU company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

82

Deep Value

Momentum

43

Neutral

Sentiment

59

Mixed

Risk resilience

50

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

InfuSystem Holdings, Inc. delivers infusion pumps, along with associated products and support services, to clients across the United States and Canada. The enterprise operates through two principal divisions: Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). The ITS segment specializes in providing electronic ambulatory infusion devices and accompanying disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy facilities. These devices are crucial for managing various cancers, including colorectal cancer, as well as for pain management and other therapeutic needs. Moreover, the company markets, leases, and rents out a selection of new and pre-owned infusion pumps (both pole-mounted and ambulatory) and other vital durable medical equipment. It also sells consumables essential for treatment. InfuSystem further extends its offerings to include biomedical recertification, maintenance, and repair services for oncology practices and diverse alternative care settings, such as home care and home infusion providers, skilled nursing facilities, pain centers, and hospitals. Additionally, InfuSystem furnishes both local and field-based customer assistance and manages dedicated pump service and repair facilities. The company was founded in 2005 and maintains its corporate headquarters in Rochester Hills, Michigan.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Carrie A. Lachance
Listed since
Dec 27, 2007
Employees
467

Market position

Day range

Current $12.21

52-week range

Current $12.21

Open
$12.165
Previous close
$12.20
Volume
97.07K
0.48× average
Average volume
202.06K
Average daily volume
Market cap
246.42M USD
Beta
1.46
Market reference 1
50-day average
$10.1468
+20.33% above average
200-day average
$9.4154
+29.68% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
185.54M USD
P/E (TTM)
29.05×
P/B (TTM)
4.16×
P/S (TTM)
1.72×
EV / EBITDA
7.36×
Earnings yield
3.58%
Free cash flow yield
8.48%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
57.45%
Operating margin
9.26%
Net margin
5.96%
Return on equity
11.56%
Return on assets
6.59%
Return on invested capital
9.25%

Financial health

Debt / equity
0.39×
Current ratio
1.8×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends63%40%17%-6%Gross margin, FY2021: 57.17%Gross margin, FY2022: 55.10%Gross margin, FY2023: 50.17%Gross margin, FY2024: 52.20%Gross margin, FY2025: 55.98%Operating margin, FY2021: 2.75%Operating margin, FY2022: 1.50%Operating margin, FY2023: 3.25%Operating margin, FY2024: 5.11%Operating margin, FY2025: 8.31%Net margin, FY2021: 1.39%Net margin, FY2022: 0.02%Net margin, FY2023: 0.69%Net margin, FY2024: 1.74%Net margin, FY2025: 4.62%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 57.17%. Gross margin FY2022 55.10%. Gross margin FY2023 50.17%. Gross margin FY2024 52.20%. Gross margin FY2025 55.98%. Operating margin FY2021 2.75%. Operating margin FY2022 1.50%. Operating margin FY2023 3.25%. Operating margin FY2024 5.11%. Operating margin FY2025 8.31%. Net margin FY2021 1.39%. Net margin FY2022 0.02%. Net margin FY2023 0.69%. Net margin FY2024 1.74%. Net margin FY2025 4.62%.

Income trends

Revenue

143.44M USD+6.36%

Operating income

11.92M USD+72.98%

Net income

6.63M USD+182.60%
Income trends across reported periods157.78M USD100.41M USD43.04M USD−14.32M USDRevenue, FY2021: 102.38M USDRevenue, FY2022: 109.91M USDRevenue, FY2023: 125.79M USDRevenue, FY2024: 134.86M USDRevenue, FY2025: 143.44M USDOperating income, FY2021: 2.82M USDOperating income, FY2022: 1.65M USDOperating income, FY2023: 4.09M USDOperating income, FY2024: 6.89M USDOperating income, FY2025: 11.92M USDNet income, FY2021: 1.42M USDNet income, FY2022: 18K USDNet income, FY2023: 872K USDNet income, FY2024: 2.35M USDNet income, FY2025: 6.63M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 102.38M USD. Revenue FY2022 109.91M USD. Revenue FY2023 125.79M USD. Revenue FY2024 134.86M USD. Revenue FY2025 143.44M USD. Operating income FY2021 2.82M USD. Operating income FY2022 1.65M USD. Operating income FY2023 4.09M USD. Operating income FY2024 6.89M USD. Operating income FY2025 11.92M USD. Net income FY2021 1.42M USD. Net income FY2022 18K USD. Net income FY2023 872K USD. Net income FY2024 2.35M USD. Net income FY2025 6.63M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue143.44M USD134.86M USD125.79M USD109.91M USD102.38M USD
Cost of goods sold63.14M USD64.46M USD62.68M USD49.35M USD43.85M USD
Gross profit80.3M USD70.4M USD63.11M USD60.56M USD58.54M USD
Selling, general, and administrative67.46M USD62.52M USD58.03M USD56.41M USD51.45M USD
Operating expenses68.38M USD63.51M USD59.02M USD58.91M USD55.72M USD
Interest expense1.3M USD1.78M USD2.17M USD1.4M USD1.38M USD
Depreciation and amortization13.29M USD12.5M USD12.51M USD13.36M USD14.63M USD
Operating income11.92M USD6.89M USD4.09M USD1.65M USD2.82M USD
Net income6.63M USD2.35M USD872K USD18K USD1.42M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 3 misses, 0 met estimates
Average EPS surprise
+30.03%
11 comparable reports
Latest EPS result
0.15
Estimate 0.11 · Beat by 42.86%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.190.10.02-0.07Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 4, 2025: actual 0.04, estimate 0.08, surprise -50.00%, Miss. Q2 2025, reported May 8, 2025: actual -0.01, estimate -0.03, surprise +66.67%, Beat. Q3 2025, reported Aug 5, 2025: actual 0.12, estimate 0.03, surprise +300.00%, Beat. Q4 2025, reported Nov 4, 2025: actual 0.11, estimate 0.08, surprise +37.50%, Beat. Q1 2026, reported Feb 24, 2026: actual 0.1, estimate 0.07, surprise +42.86%, Beat. Q2 2026, reported May 7, 2026: actual 0.05, estimate 0.04, surprise +25.00%, Beat. Q3 2026, reported Aug 4, 2026: actual 0.15, estimate 0.105, surprise +42.86%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate 0.12, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates38.88M36.65M34.42M32.19MQ1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 4, 2025: actual 33.85M USD, estimate 33.76M USD, surprise +0.28%, Beat. Q2 2025, reported May 8, 2025: actual 34.72M USD, estimate 36.07M USD, surprise -3.74%, Miss. Q3 2025, reported Aug 5, 2025: actual 36M USD, estimate 37.38M USD, surprise -3.69%, Miss. Q4 2025, reported Nov 4, 2025: actual 36.49M USD, estimate 36.68M USD, surprise -0.52%, Miss. Q1 2026, reported Feb 24, 2026: actual 36.23M USD, estimate 36.68M USD, surprise -1.23%, Miss. Q2 2026, reported May 7, 2026: actual 33.68M USD, estimate 34.33M USD, surprise -1.89%, Miss. Q3 2026, reported Aug 4, 2026: actual 36.93M USD, estimate 36.35M USD, surprise +1.60%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate 37.39M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

4 ratings

Limited analyst sample: 4 ratings. Interpret the distribution with caution.

Strong buy00%
Buy4100%
Hold00%
Sell00%
Strong sell00%

Recent analyst actions

2 institutions
B. Riley SecuritiesmaintainBuy

INFU news

INFU peers

ETFs holding INFU

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research INFU

research.disclaimer